2015 Controlled Substances Labelling 
The Checkup by Singlecare
OCTOBER 4, 2023
In 2015, the FDA approved Vyvanse to be used in the treatment of binge eating disorder. In fact, the official FDA guidance about Vyvanse specifically warns against off-label use (a use that is not approved by the FDA) for weight loss, stating, “Vyvanse is not indicated or recommended for weight loss. Sources Vyvanse Label.
The Checkup by Singlecare
MAY 1, 2024
It is a Drug Enforcement Administration (DEA) controlled substance in the Schedule II category. Non-amphetamine-based ADHD treatments, such as Strattera , are not controlled substances. Food and Drug Administration (FDA) in 2007 for treatment and symptom control in ADHD. Vyvanse was initially approved by the U.S.
The Checkup by Singlecare
JANUARY 15, 2024
When using Adderall off-label for depression, there are many things prescribers consider. Some providers will prescribe Adderall or another stimulant medication off-label to help some patients who are struggling to find a treatment or combination of treatments to help them manage their mental health conditions.
Expert insights. Personalized for you.
Let's personalize your content